amifostine anhydrous has been researched along with Peritoneal Carcinomatosis in 4 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 1 |
| Keita, H | 1 |
| Berry, E | 1 |
| Matthews, KS | 1 |
| Singh, DK | 1 |
| Buttin, BM | 1 |
| Lurain, JR | 1 |
| Alvarez, RD | 1 |
| Schink, J | 1 |
| Safra, T | 1 |
| Jeffers, S | 1 |
| Sorich, J | 1 |
| Muggia, FM | 1 |
| Vaira, M | 1 |
| Barone, R | 1 |
| Aghemo, B | 1 |
| Mioli, PR | 1 |
| De Simone, M | 1 |
1 trial available for amifostine anhydrous and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
[Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Topics: Amifostine; Antineoplastic Agents; Carcinoma; Cisplatin; Humans; Hyperthermia, Induced; Intraoperati | 2001 |
3 other studies available for amifostine anhydrous and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
Gemcitabine plus cisplatin combination given with amifostine (GAP) to heavily pretreated patients with gynecologic and peritoneal cancers: tolerance and activity in ovarian cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; D | 1998 |